THE POWER OF PREEMPTION
OMIDRIA
®
is the first and only FDA-approved drug that provides direct,
continuous intracameral delivery of NSAID and mydriatic/anti-miotic
therapy during cataract surgery
1
®
LEARN MORE AT
ASCRS
ASOA BOOTH #1117
CHOOSE OMIDRIA FOR YOUR NEXT CATARACT SURGERY PATIENT
•
Preempt miosis — Maintain pupil dilation and optimize your operative field
1,2
•
Block the surgically induced inflammatory cascade — Continuous delivery of
OMIDRIA in the irrigation solution provides steady-state concentrations of
ketorolac and phenylephrine at the site of surgery
1
•
Reduce postoperative pain — Patients are more likely to be pain-free postoperatively,
less likely to have moderate-to-severe pain, and less likely to use oral analgesics
1,3
•
Eliminate the risks and liabilities of compounded products — OMIDRIA is FDA-approved;
it is GMP manufactured and the safety, efficacy, and drug product quality have been
verified by the FDA
1,4
•
Avoid coverage and reimbursement difficulties —
Have confidence in reimbursement and provide your
patients with the additional protection of OMIDRIAssure™
Visit OMIDRIAssure.com or call 1-877-OMIDRIA
(1-877-664-3742) 9 am–6 pm ET, Monday–Friday
Visit www.omidria.com
